Amerisourcebergen Corp ABC
We take great care to ensure that the data presented and summarized in this overview for AMERISOURCEBERGEN CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ABC
View all-
Vanguard Group Inc Valley Forge, PA23.4MShares$4.33 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY17.8MShares$3.3 Billion0.08% of portfolio
-
State Street Corp Boston, MA9.19MShares$1.7 Billion0.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD7.72MShares$1.43 Billion0.26% of portfolio
-
Geode Capital Management, LLC Boston, MA5.29MShares$980 Million0.06% of portfolio
-
Jpmorgan Chase & CO New York, NY4.68MShares$866 Million0.06% of portfolio
-
Boston Partners Boston, MA4.51MShares$835 Million0.92% of portfolio
-
Invesco Ltd. Atlanta, GA4.01MShares$742 Million0.12% of portfolio
-
Wellington Management Group LLP Boston, MA3.97MShares$735 Million0.13% of portfolio
-
Bank Of America Corp Charlotte, NC3.96MShares$734 Million0.05% of portfolio
Latest Institutional Activity in ABC
Top Purchases
Top Sells
About ABC
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in the companion animal and production animal markets, as well as demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
Insider Transactions at ABC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 20
2025
|
Robert P. Mauch President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,144
-3.0%
|
$776,128
$362.07 P/Share
|
|
Nov 20
2025
|
Robert P. Mauch President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,790
+7.49%
|
-
|
|
Nov 20
2025
|
Pawan Verma EVP, Chief Data & Info Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,010
-16.4%
|
$365,620
$362.07 P/Share
|
|
Nov 20
2025
|
Pawan Verma EVP, Chief Data & Info Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,974
+24.27%
|
-
|
|
Nov 20
2025
|
Lazarus Krikorian SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
421
-1.95%
|
$152,402
$362.07 P/Share
|
|
Nov 20
2025
|
Lazarus Krikorian SVP & Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,023
+4.52%
|
-
|
|
Nov 20
2025
|
Elizabeth S Campbell Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
736
-2.63%
|
$266,432
$362.07 P/Share
|
|
Nov 20
2025
|
Elizabeth S Campbell Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
1,590
+5.38%
|
-
|
|
Nov 20
2025
|
James F Cleary Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
824
-0.61%
|
$298,288
$362.07 P/Share
|
|
Nov 20
2025
|
James F Cleary Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,876
+1.36%
|
-
|
|
Nov 20
2025
|
Silvana Battaglia Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
406
-1.94%
|
$146,972
$362.07 P/Share
|
|
Nov 20
2025
|
Silvana Battaglia Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
932
+4.27%
|
-
|
|
Nov 18
2025
|
Robert P. Mauch President & CEO |
SELL
Open market or private sale
|
Direct |
5,096
-7.19%
|
$1,865,136
$366.64 P/Share
|
|
Nov 18
2025
|
Robert P. Mauch President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,763
+5.04%
|
$323,618
$86.09 P/Share
|
|
Nov 13
2025
|
Robert P. Mauch President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
18,677
-21.78%
|
$5,827,224
$312.53 P/Share
|
|
Nov 13
2025
|
Robert P. Mauch President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
42,944
+33.37%
|
-
|
|
Nov 13
2025
|
Elizabeth S Campbell Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
9,532
-26.54%
|
$2,973,984
$312.53 P/Share
|
|
Nov 13
2025
|
Elizabeth S Campbell Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
20,613
+36.46%
|
-
|
|
Nov 13
2025
|
James F Cleary Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,901
-9.41%
|
$4,337,112
$312.53 P/Share
|
|
Nov 13
2025
|
James F Cleary Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,062
+16.9%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 117K shares |
|---|---|
| Exercise of conversion of derivative security | 197K shares |
| Open market or private sale | 1.5M shares |
|---|---|
| Payment of exercise price or tax liability | 68.8K shares |
| Other acquisition or disposition | 6.16M shares |